BGHL (GBP): NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
13
BGHL (GBP): NAV(s)

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

Close of business 07 Feb 2019.

Estimated NAV

  Euro Shares Sterling Shares
Estimated NAV €  21.9785 £  19.6499
Estimated MTD return  0.24 %  0.26 %
Estimated YTD return  -0.12 %  0.03 %
Estimated ITD return  119.79 %  96.50 %

NAV and returns are calculated net of management and performance fees

Market information

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  17.00 N/A
Premium/discount to estimated NAV  -22.65 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,500.00
Premium/discount to estimated NAV N/A  -23.66 %

Transactions in own securities purchased into treasury

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

           

                                           

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

BGHL Capital

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,782,231  608,712
Held in treasury N/A N/A
Shares Issued  28,782,231  608,712

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  179.2790

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

  • all investment is subject to risk;
  • results in the past are no guarantee of future results;
  • the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and
  • if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading